Trade Allakos Inc. - ALLK CFD

Allakos Inc. Company profile

About Allakos Inc

Allakos Inc. is a clinical stage biotechnology company. The Company is developing therapeutics, which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Its advanced antibodies are lirentelimab (AK002) and AK006. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are widely distributed in the body and play a central role in the inflammatory response. It is developing AK002 for the treatment of eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic duodenitis (EoD), atopic dermatitis, chronic spontaneous urticaria and additional indications. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It also developed a formulation of lirentelimab for subcutaneous (SC) administration. The Company is also developing additional antibodies targeting inhibitory receptors expressed on key disease-driving immune cells.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Allakos Inc revenues was not reported. Net loss increased 76% to $269.9M. Higher net loss reflects Research and Development - Balancing increase of 88% to $176.5M (expense), General and Administrative - Balancing increase of 49% to $44.2M (expense), Stock-based Compensation in SGA increase of 42% to $31M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$3.10 to -$5.01.